Acer Therapeutics and Relief Therapeutics today announced FDA acceptance for filing of New Drug Application for ACER-001 to treat Urea Cycle Disorders. PDUFA target action date set for June 5, 2022. https://tinyurl.com/ymd4nbmd #AcerTherapeutics #UCDs #investigational
Acer Therapeutics and Relief Therapeutics today announced FDA acceptance for filing of New Drug Application for ACER-001 to treat Urea Cycle Disorders. PDUFA target action date set for June 5, 2022. https://t.co/6EFdcJhsYU#AcerTherapeutics#UCDs#investigational
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.